Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus ZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus ZIDE.
HYDROCHLOROTHIAZIDE INTENSOL vs ZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride and increasing excretion of water, sodium, chloride, potassium, and bicarbonate.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
10 mg orally once daily.
None Documented
None Documented
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Clinical Note
moderateBendroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digoxin."
Clinical Note
moderateMethyclothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderate6-8 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (eGFR <30 mL/min).
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Renal: 70% unchanged; Biliary/fecal: 30% (as metabolites and parent compound).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."